Wednesday, February 21, 2018
Health

USF to begin analyzing patient genetics at new Heart Institute

TAMPA — A simple blood test is launching the University of South Florida's ambitions to become a leader in treating heart disease, the nation's No. 1 killer.

That's all it takes to run the genetic tests that USF leaders hope to translate into medical advancements at their proposed $50 million USF Heart Institute, whose development is under way with $9 million in tax money.

The results could help doctors, for example, select the best drug for patients suffering from heart failure, a slow killer for which treatment can be a guessing game. That's the promise of new research by USF's Dr. Stephen Liggett, who has identified a pair of genetic signatures helpful in predicting the effectiveness of a certain beta-blocker drug.

Early next year, a new partnership between USF and the American College of Cardiology aims to expand on this type of genetic discovery. The groups plan to work together on a clinical trial to sequence the DNA of 1,000 Tampa patients. It's a test run for larger efforts to link patient genetic information with a database of clinical information.

The goal is to create new therapies for cardiac patients based on their unique genetic makeup.

"It's a ripe area of research," said Dr. William Oetgen, a professor at the Georgetown University School of Medicine and the ACC's senior vice president of science and quality. "We don't know where it's going to go, or what discoveries are going to be made. "

•••

The Heart Institute is a top priority for USF's medical school. This spring, state legislators launched it with $6.9 million in tax money, allowing USF to start the design of a 100,000-square-foot research building on its main campus in north Tampa.

Hillsborough County commissioners awarded $2 million more. University officials hope to break ground in July on the institute, which is expected to employ at least 56 people making an average of $76,000 annually.

Researchers will seek to identify genetic markers that indicate which patients are predisposed to heart disease, so they can be targeted for early intervention. And they will test emerging stem cell therapies that could help repair heart damage.

The work also will build on research like the recently published work of Liggett, USF's new vice-dean for personalized medicine and genomics.

While in his previous post at the University of Maryland, he helped lead a national team of investigators examining genetic markers to improve treatment of heart failure. The researchers sought to identify which patients are most likely to respond to bucindolol, one of about a dozen beta-blockers on the market.

About half of U.S. patients diagnosed with heart failure — when the heart can't pump enough blood and oxygen to support the body's organs — die within five years. Physicians have a narrow window to get patients started on the right treatment, Liggett said, because it can take a year for drugs to take effect.

"In heart failure, we have a substantial problem, because we are unable to determine who is going to respond to what drugs," he said. "We are in a situation that some have called trial and error."

The study, published in the journal PLoS One, followed about 1,000 patients for five years. While they were receiving treatment, researchers analyzed their genetics, identifying a pair of genetic signatures predictive of a strong response to bucindolol.

These findings have been used to develop a blood test to help doctors know which patients are likely to get better on the medication from the beginning of their treatment course, Liggett said.

It's the kind of development that could make a difference to Roger Ramey. The 59-year-old Citrus Park man had a heart attack in 2006 and later was diagnosed with heart failure, which can develop after heart attacks. Finding the right medication regimen has been an ongoing struggle.

"Every time I'd go in the hospital, they wanted to mess with that," said Ramey, a USF patient, who feels weak and short of breath when his drug levels are off. "I wouldn't have gone through all the times where they were guessing on the dosage."

•••

The next step for USF is to prove its ability to carry out genetic testing on a large scale — and marry the results to a rich database of patient clinical information maintained by the American College of Cardiology.

That's the goal of a joint clinical trial to begin at USF early next year.

"It's proof of concept. It's never been done," said Dr. Leslie Miller, director of the USF Heart Institute.

He said success could result in national expansion of the study to involve thousands of patients. The end goal is "developing whole new therapeutics based entirely off of the correlation of genomic findings and the clinical database," Miller said.

To participate, cardiac patients would have to agree to have two tubes of blood drawn for DNA sequencing. The results would be confidential, Miller said. Participating patients would get to be the first to try out any new therapies developed.

The concept is similar to M2Gen, a for-profit startup of Moffitt Cancer Center, which also seeks to develop new drugs from its large database of frozen tumor samples. Yet M2Gen, a collaboration with pharmaceutical giant Merck & Co., so far hasn't generated the blockbuster drugs that some envisioned when it was announced in late 2006.

And using patient genetics to tailor cancer treatments is much farther along, said Oetgen of the national cardiologists' society.

"The likelihood of finding a blockbuster drug or discovery is higher in oncology, because they are dealing with literally life and death situations over very short time frames," Oetgen said.

In cardiac care, "it's likely that patients will benefit," he added. "But the scale and the magnitude of the benefit is to be determined."

Letitia Stein can be reached at [email protected] or (727) 893-8330.

Comments
Preventive treatment for peanut allergies succeeds in study

Preventive treatment for peanut allergies succeeds in study

The first treatment to help prevent serious allergic reactions to peanuts may be on the way. A company said Tuesday that its daily capsules of peanut flour helped sensitize children to nuts in a major study. Millions of children have peanut allergies...
Published: 02/20/18
Doctors were wrong when they told her immunotherapy wouldn’t cure her cancer

Doctors were wrong when they told her immunotherapy wouldn’t cure her cancer

No one expected the four young women to live much longer. They had an extremely rare, aggressive and fatal form of ovarian cancer. There was no standard treatment.The women, strangers to one another living in different countries, asked their doctors ...
Published: 02/20/18

Hernando Bloodmobile for Feb. 23

Bloodmobile locationsLifeSouth Community Blood Center will have blood drives at the following off-site locations during the coming week:Feb. 23: 10 a.m. to 3 p.m., Walmart, 13300 Cortez Blvd., Spring Hill; 10:30 a.m. to 5:30 p.m., Dickey’s Barbecue P...
Published: 02/20/18
Be prepared to help save a life: Learn CPR

Be prepared to help save a life: Learn CPR

70 percent of cardiac arrests outside hospitals happen at home. American Heart Association 3 a.m. Jan. 4, 2016. Lisa Peters of St. Petersburg is awakened by her husband, Rick, making strange gasping sounds. She can’t wake him. He feels cold. Only 46...
Published: 02/16/18

Step by step, ramp up your daily activity

Jae Bermanhe Washington Post There are many reasons that people avoid exercise. Time is an obvious one. Our lives are already busy — who has time to work out? Money is another common excuse. Gym memberships and equipment can get pricey.People often w...
Published: 02/16/18
Put Alaskan king crab leg shells to work in a creamy, dreamy bisque

Put Alaskan king crab leg shells to work in a creamy, dreamy bisque

Nothing says indulgence like noshing on some seriously giant Alaskan king crab legs. They’re not just tasty, they’re a low-fat source of protein: One leg has about 25 grams of protein and a host of vitamins and minerals (including sodium, incidentall...
Published: 02/15/18
Avocado toast gets a persimmon twist

Avocado toast gets a persimmon twist

You’ve likely seen persimmon in the grocery store and then shied away from it, not quite sure what to do with it. The most common variety in the United States is the fuyu persimmon, also called Japanese persimmon, and it looks similar to a slightly f...
Published: 02/15/18
News co-anchor Dan Harris delves into meditation, and why being distracted is ‘a victory’

News co-anchor Dan Harris delves into meditation, and why being distracted is ‘a victory’

Emma Seppalahe Washington PostDan Harris is co-anchor of ABC’s Nightline and the weekend editions of Good Morning America. His first book, 10% Happier, was a No. 1 New York Times bestseller. He later launched the 10% Happier podcast and an app called...
Published: 02/15/18

Mayo Clinic Q&A: exercise stress tests; breast self-awareness versus self-exams

DON’T SWEAT THE EXERCISE STRESS TESTI have a treadmill stress test scheduled to look for heart disease. I know this involves exercising, and I’m worried that I’m not physically up to it. Is there another way to gather this information?Yes. There’s an...
Published: 02/15/18
Gay doctor takes a drug to prevent HIV. Then he couldn’t get disability insurance

Gay doctor takes a drug to prevent HIV. Then he couldn’t get disability insurance

Three years ago, Dr. Philip J. Cheng, a urology resident at Harvard’s Brigham and Women’s Hospital, nicked himself while preparing an HIV-positive patient for surgery.Following hospital protocol, he took a one-month course of Truvada, a cocktail of t...
Published: 02/15/18